Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's repeatable business is escalating. We need to look for management's own words conveying that the deals, orders, contracts, projects, customers, sites, or programs are individually bigger, broader, or longer than before. Let's scan the transcript for any such statements. The call covers various topics: sales growth, Pro customer growth, supply chain, etc. We need to find if management explicitly says that the size of individual orders, contracts, or projects is increasing. Key points from the call: - Marvin Ellison mentions "our momentum continued this quarter with comparable sales up 2.2%... on top of over 30% growth last year." That's about sales growth, not necessarily unit size. - He talks about "growing our share of wallet with both Pro and DIY customers" and "Total Home Strategy." - Bill Boltz discusses product categories, supply chain, etc. - Joe McFarland talks about Pro comps, PPI initiatives, etc. - David Denton discusses financials. We need to look for any mention of average order size, ticket size, project size, etc. There is a mention of "comparable average ticket increased 9.7% driven primarily by higher ticket sales of appliances and flooring, as well as product inflation." That's about average ticket, but that could be due to price increases or mix, not necessarily that each new engagement is larger. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. That would be like each new order or contract is bigger than the last. The average ticket increase might be due to inflation or mix, not necessarily that the same type of business is getting bigger per instance. Also, there is mention of "Pro growth over 16% and over 43% on a 2-year basis." That's about sales growth, not necessarily that each Pro customer is spending more per order. They might be gaining more customers or more frequent purchases. We need to see if management explicitly says that the size of individual projects, orders, or contracts is escalating.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.